# Japan Dry Age Related Macular Degeneration Market

> Japan Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals clinics, diagnostic centers, academic research institutes) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.52%
- **2024:** $ 297.5 Million
- **2025:** $ 322.19 Million
- **2035:** $ 660.62 Million
- **Key Players:** Roche (JP), Novartis (JP), Regeneron Pharmaceuticals (JP), Bayer (JP), Pfizer (JP), Santen Pharmaceutical (JP), Astellas Pharma (JP), Otsuka Pharmaceutical (JP), Eisai (JP)

**Report ID:** MRFR/MED/43217-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/japan-dry-age-related-macular-degeneration-market-44897

---

## Market Summary

## **Japan Dry Age-Related Macular Degeneration (AMD) Market Overview**

As per MRFR analysis, the Japan Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 275.0 (USD Million) in 2023. The Japan Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 300.0(USD Million) in 2024 to 900.0 (USD Million) by 2035. The Japan Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035).

**Key Japan Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted**

The Japan Dry Age-Related Macular Degeneration (AMD) Market is witnessing significant trends driven by an increasingly aging population, which is a primary market driver. With nearly a third of Japan's population being over 65 years old, there is a growing prevalence of age-related eye diseases, including dry AMD. This demographic shift is prompting healthcare authorities and providers to focus on early diagnosis and preventative measures, emphasizing regular eye examinations for senior citizens. 

Additionally, advancements in technology and research have led to innovative treatment options, including new pharmaceuticals aimed at managing the symptoms and progression of dry AMD.There is a greater focus on education and awareness, which has already given many different market players a chance to interact with patients and educational campaigns for health professionals. Now, there is more interest in genetic testing and personalized medicine opportunities for AMD patients. Many businesses are now starting to implement targeted therapies that modify treatment on the basis of genetic makeup.

The growth in collaboration between ophthalmologists and other sectors has significantly improved the innovation in treatments.

Clinical trials focusing on new drug formulations and delivery systems are on the rise, aiming to enhance efficacy and minimize side effects. Furthermore, the Japanese government's initiatives to promote healthcare technology adoption are likely to support advancements in diagnostic tools and treatment protocols for AMD. This collaborative approach in the healthcare sector exemplifies the commitment to addressing AMD's challenges and improving patient outcomes in Japan.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Japan Dry Age-Related Macular Degeneration (AMD) Market Drivers**

**Aging Population in Japan**

Japan has one of the oldest populations in the world, with over 28% of its citizens aged 65 and older, as reported by the Japan Statistical Yearbook. This demographic shift drives the prevalence of age-related disorders, including dry age-related macular degeneration (AMD).

Consequently, the increasing number of older adults is significantly impacting the Japan Dry Age-Related Macular Degeneration (AMD) Market Industry, resulting in a growing demand for effective treatment and management options for AMD.The Ministry of Health, Labour and Welfare has also observed that the incidence of visual impairments, such as AMD among the elderly, is predicted to rise by over 40% in the next decade, highlighting an urgent need for medical advancements and healthcare services tailored to this age group.

With this rising demand, the industry is expected to see significant growth as healthcare providers and pharmaceutical companies invest in research and development of innovative therapeutic options.

**Increasing Awareness and Early Detection**

There has been a concerted effort in Japan to increase awareness regarding dry AMD and the importance of early detection and treatment. Campaigns led by organizations such as the Japan Eye Institute are pushing for regular eye check-ups among older adults. An increase in the number of routine eye examinations is expected to lead to earlier diagnoses of AMD.

Recent data indicates that, due to improved awareness initiatives, more than 30% of the elderly population is getting regular eye check-ups, as opposed to only about 15% a decade ago.This surge in awareness directly contributes to growth in the Japan Dry Age-Related Macular Degeneration (AMD) Market Industry, as earlier detection typically translates to a higher likelihood of effective treatment and management, consequently boosting the market's value.

**Advancements in Treatment Options**

Innovations in the development of treatment options for dry AMD are on the rise, with research being spearheaded by reputable pharmaceutical companies within Japan, such as Takeda Pharmaceutical Company. Recent advancements in therapies, including intravitreal injections and oral medications aimed at slowing disease progression, have shown promising results in clinical trials.

This progress is vital as the Japanese Ministry of Health has reported that about 1.5 million people suffer from some form of AMD, indicating a large patient pool that can benefit from these therapies.The continuous innovation in treatment methods and the approval of new medications are crucial for driving the Japan Dry Age-Related Macular Degeneration (AMD) Market Industry forward, as they provide new avenues for managing the condition and improving the quality of life for patients.

**Japan Dry Age-Related Macular Degeneration (AMD) Market Segment Insights**

**Dry Age-Related Macular Degeneration (AMD) Market Stage Insights**

The Japan Dry Age-Related Macular Degeneration (AMD) Market shows a clear segmentation based on the stage of the disease, which is critical for understanding patient needs and treatment approaches tailored to each progression level. In Japan, where the aging population is rapidly increasing, the prevalence of early age-related macular degeneration has become a priority for healthcare providers and policymakers.

This stage, often characterized by the presence of drusen, plays a pivotal role in shaping intervention strategies, as early detection is essential for effective management and slowing disease progression.Intermediate age-related macular degeneration marks a transition where patients exhibit greater visual disturbances, creating significant demands on the healthcare system for timely and appropriate treatment. It is during this stage that the focus on innovative therapies and clinical trials is particularly robust, aiming to prevent further deterioration of vision. 

Late age-related macular degeneration is the most serious stage, typically leading to severe vision loss, thereby increasing the urgency for advanced therapies and rehabilitation services.With the Japan Dry Age-Related Macular Degeneration (AMD) Market challenging healthcare entities to adapt to the needs of a growing patient demographic, the different stages inform various market growth drivers. Recognizing the shifting landscape defined by risk factors like genetics, diet, and lifestyle habits offers opportunities for targeted educational campaigns aimed at enhancing early diagnosis and treatment adherence. 

Moreover, advancements in diagnostics and therapeutic areas are becoming increasingly significant in addressing the challenges posed by the disease's progression across its different stages.The multi-faceted nature of this segment underscores the importance of comprehensive, stage-oriented strategies to address the evolving needs of the population, especially in urban centers where healthcare infrastructure is more developed. 

Insights drawn from the Japan Dry Age-Related Macular Degeneration (AMD) Market statistics reveal that as public awareness rises and healthcare initiatives expand, collaboration among stakeholders becomes essential for optimizing resource allocation and enhancing patient outcomes. The strategic focus on the stages of age-related macular degeneration not only drives research and development in the sector but also consolidates efforts towards effective care models that can significantly impact the quality of life for aging individuals.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights**

The Japan Dry Age-Related Macular Degeneration (AMD) Market reflects a notable correlation between age demographics and the prevalence of this eye condition, particularly among older populations. Individuals above 75 years significantly contribute to market development, often requiring specialized treatments and care due to the higher incidence of vision loss associated with AMD in this age group.

Meanwhile, those above 60 years also present substantial demand, as they are increasingly diagnosed with early symptoms of dry AMD, necessitating regular monitoring and therapeutic interventions.Furthermore, the above 40 years age group is becoming more significant as awareness of AMD grows, prompting early screening and preventive measures.

 With an aging population in Japan, supported by government initiatives emphasizing eye health, the market is poised for growth driven by the needs of these age brackets. The prevalence in these segments not only highlights the urgency of addressing AMD but also opens opportunities for innovation in treatment and care solutions tailored to the specific needs of each group. The Japan Dry Age-Related Macular Degeneration (AMD) Market statistics indicate that addressing these age-related challenges is fundamental for advancing ocular healthcare in the country.

**Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights**

The Japan Dry Age-Related Macular Degeneration (AMD) Market, particularly in the realm of Diagnosis and Treatment, plays a crucial role in addressing the growing prevalence of this age-related condition. The rising number of elderly individuals in Japan, coupled with increased awareness and advances in diagnostic technologies, is propelling market growth. The diagnosis segment focuses on early detection through innovative imaging techniques and screening processes that allow for timely intervention, which is pivotal in managing the disease's progression.Meanwhile, treatment options are evolving rapidly, with a strong emphasis on developing effective therapies that can enhance visual outcomes for patients.

Comprehensive approaches often blend pharmacological treatments with lifestyle modifications tailored to individual patient needs, addressing both physical and emotional aspects of care. 

This dual focus on diagnosis and treatment not only aims to improve patient’s quality of life but also highlights the significance of ongoing research and development in the sector. In Japan, government initiatives and healthcare policies further support advancements in this area, fostering an environment conducive to growth and innovation in Dry AMD management.With a significant demographic shift towards an aging population, the Diagnosis and Treatment segment in the Japan Dry Age-Related Macular Degeneration (AMD) Market is expected to continue evolving as a vital component of the healthcare landscape.

**Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights**

The Route of Administration segment within the Japan Dry Age-Related Macular Degeneration (AMD) Market is crucial as it impacts efficacy and patient compliance significantly. In Japan, the increasing prevalence of AMD has driven demand for various administration methods, which include oral medications and injectables. Oral administration is often preferred due to ease of use, allowing for improved patient adherence to treatment regimens, particularly among the elderly demographic that constitutes a large portion of AMD patients.

Conversely, injectables play a pivotal role in delivering targeted therapies with potentially faster results, making them significant in treating advanced cases of AMD.The development of innovative injectable therapies has contributed to this route’s dominance in clinical settings. 

Furthermore, advancements in drug formulation and delivery systems are expected to enhance these administration routes, with a focus on improving treatment outcomes. The Japanese healthcare system is keen on integrating efficient and effective administration methods, which aligns with the growing market trends where patient-centric approaches are increasingly prioritized. 

This segment's growth is supported by ongoing research, development initiatives, and a healthcare environment that fosters innovation in treatment approaches for AMD.Thus, the Route of Administration segment is not only vital for standard practices in Japan but also for the strategic development of the industry moving forward.

**Dry Age-Related Macular Degeneration (AMD) Market End Users Insights**

The Japan Dry Age-Related Macular Degeneration (AMD) Market reflects a diverse landscape, particularly within the End Users segment, which includes hospitals clinics, diagnostic centers, and academic research institutes. Hospitals and clinics play a crucial role in the management and treatment of AMD, providing essential services that cater to the increasing aging population in Japan, known for having one of the highest life expectancies globally. 

Diagnostic centers are also significant, as they employ advanced imaging techniques crucial for early detection and monitoring of the disease, contributing to better patient outcomes.Academic and research institutes are instrumental in driving innovations and breakthroughs in AMD treatments through clinical trials and research initiatives, ensuring that the market continues to evolve in ways that address the specific needs of patients. 

This emphasis on research and development aligns with Japan's commitment to improving healthcare and treatment options, thus fostering a robust environment for the Japan Dry Age-Related Macular Degeneration (AMD) Market to flourish. As the population ages, the focus on these End Users positions them as vital players in tackling the growing prevalence of AMD, responding to the urgent need for effective management strategies.

**Japan Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights:**

The competitive landscape of the Japan Dry Age-Related Macular Degeneration (AMD) Market is shaped by a combination of established players and emerging companies, all vying for a significant share in a growing sector driven by an aging population and increased awareness of eye health. As the prevalence of AMD steadily rises among the elderly demographic in Japan, pharmaceutical and biopharmaceutical companies are focusing on developing innovative treatments and therapies to address unmet medical needs. Collaboration with healthcare providers and investment in research and development are essential strategic approaches for these companies to differentiate their offerings in this competitive environment. 

The market dynamics are influenced by regulatory approvals, market access strategies, and the effectiveness of the product pipeline, which together define the contours of competition.AbbVie has established a notable presence in the Japan Dry Age-Related Macular Degeneration (AMD) Market, primarily through the development and commercialization of advanced therapeutic options for ophthalmic conditions. The company's robust research initiatives have positioned it well to address the specific needs of AMD patients in Japan, where the demand for effective treatments continues to grow. AbbVie's strengths lie in its extensive experience and expertise in biopharmaceuticals, particularly its strong focus on innovation and patient-centric solutions. 

The company's ability to leverage its existing research capabilities, coupled with strategic partnerships with local entities, enhances its competitive edge, allowing it to navigate the unique regulatory landscape of Japan effectively. This strategic positioning enables AbbVie to remain competitive and responsive to market needs.Bayer also plays a significant role in the Japan Dry Age-Related Macular Degeneration (AMD) Market with its well-regarded portfolio of treatments aimed at managing AMD symptoms and improving patient outcomes. Bayer's key products in this area, including a range of age-related therapies, are backed by substantial clinical data and a commitment to advancing eye health. 

The company's presence in Japan is bolstered by its strong reputation within the pharmaceutical industry, significant investments in research and development, and a proactive approach to merging innovative technologies with patient needs. Bayer’s strengths include a solid distribution network, consistent product quality, and strategic collaborations, which have been instrumental in maintaining its market position. Any recent mergers or acquisitions have also allowed Bayer to enhance its capabilities in ophthalmology and broaden its market reach, positioning the company favorably within the context of AMD treatment advancements in Japan.

**Key Companies in the Japan Dry Age-Related Macular Degeneration (AMD) Market Include:**

- AbbVie
- Bayer
- Horizon Therapeutics
- Johnson and Johnson
- Genentech
- Roche
- Alcon
- Opthea
- Eyepoint Pharmaceuticals
- Novartis
- Santen Pharmaceutical
- Astellas Pharma
- Eyenovia
- Regeneron Pharmaceuticals
- Apellis Pharmaceuticals

**Japan Dry Age-Related Macular Degeneration (AMD) Market Industry Developments**

The Japan Dry Age-Related Macular Degeneration (AMD) Market has recently seen significant news developments and changes. In October 2023, Genentech announced progress in their clinical trial regarding innovative treatments for AMD, potentially impacting patient outcomes in Japan. 

Additionally, AbbVie and Horizon Therapeutics have broadened their collaborative efforts to accelerate research in AMD therapies, contributing to the evolving landscape of this market. Major players like Novartis and Roche have reported increased market valuation as a result of heightened demand for AMD treatments amid Japan's aging population. Notable growth in research and development expenditure in the ophthalmic segment, particularly focusing on dry AMD, has been observed, reflecting Japan's commitment to enhancing eye health care. Companies such as Astellas Pharma and Santen Pharmaceutical are aligning their strategies to capture market opportunities, following trends in regenerative treatments. 

Furthermore, in August 2022, Eyenovia announced a strategic partnership with a local firm to enhance the reach of its innovative delivery systems in Japan, thus diversifying treatment modalities in AMD. The collaborative efforts and rising investments have kept the Japanese AMD market dynamic, catering to the growing need for effective treatment solutions in a rapidly aging society.

**Japan Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights**

## Market Drivers

### Emerging Treatment Options

The Japan [Dry Age Related Macular Degeneration Amd](https://www.marketresearchfuture.com/reports/dry-age-related-macular-degeneration-amd-market-10657) Market is poised for growth due to the emergence of novel treatment options. Recent developments in pharmacological therapies, such as anti-VEGF agents and complement inhibitors, show promise in managing dry AMD. These innovative treatments may improve visual outcomes and slow disease progression, thereby attracting more patients to seek care. Additionally, clinical trials are underway to evaluate the efficacy of these new therapies, which could further enhance the treatment landscape. As these options become available, they are likely to drive demand within the Japan Dry Age Related Macular Degeneration Amd Market, offering hope to patients and healthcare providers alike.

### Rising Aging Population in Japan

The Japan Dry Age Related Macular Degeneration Amd Market is significantly influenced by the increasing aging population. As of 2025, approximately 28% of Japan's population is aged 65 and older, a demographic that is particularly susceptible to dry AMD. This trend is expected to continue, leading to a higher incidence of age-related eye diseases. The growing number of elderly individuals necessitates enhanced healthcare services and treatment options, thereby driving demand within the market. Furthermore, the Japanese government has recognized this demographic shift and is likely to implement policies aimed at improving eye health services. This focus on geriatric care may lead to increased funding for research and development in the Japan Dry Age Related Macular Degeneration Amd Market, ultimately benefiting patients and healthcare providers alike.

### Increased Awareness and Education

Awareness regarding dry AMD is gradually increasing among the Japanese population, which is positively impacting the Japan Dry Age Related Macular Degeneration Amd Market. Educational campaigns by healthcare organizations and non-profits are informing the public about the symptoms and risks associated with dry AMD. This heightened awareness encourages individuals to seek early diagnosis and treatment, which is crucial for managing the disease effectively. As more people become informed about the importance of regular eye examinations, the demand for screening and therapeutic options is likely to rise. Consequently, this trend may lead to a more proactive approach to eye health, further stimulating growth in the Japan Dry Age Related Macular Degeneration Amd Market.

### Advancements in Diagnostic Technologies

The Japan Dry Age Related Macular Degeneration Amd Market is experiencing growth due to advancements in diagnostic technologies. Innovations such as optical coherence tomography (OCT) and fundus photography have improved the accuracy of dry AMD diagnosis. These technologies enable healthcare professionals to detect the disease at earlier stages, which is essential for effective management. As diagnostic tools become more accessible and affordable, healthcare providers are likely to adopt them more widely, leading to increased patient referrals for treatment. This shift not only enhances patient outcomes but also contributes to the overall expansion of the Japan Dry Age Related Macular Degeneration Amd Market, as more individuals are diagnosed and treated.

### Government Support and Policy Initiatives

The Japan Dry Age Related Macular Degeneration Amd Market benefits from government support and policy initiatives aimed at improving eye health. The Japanese government has implemented various programs to promote research and development in ophthalmology, particularly focusing on age-related diseases. These initiatives may include funding for clinical trials and partnerships with pharmaceutical companies to expedite the development of new treatments. Furthermore, public health campaigns aimed at educating the population about eye health are likely to enhance early detection and treatment of dry AMD. This supportive environment fosters innovation and growth within the Japan Dry Age Related Macular Degeneration Amd Market, ultimately benefiting patients and healthcare providers.

## Future Outlook

The Japan Dry Age Related Macular Degeneration market is projected to grow at a 7.52% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment options.

**New opportunities:**

- Development of telemedicine platforms for remote patient monitoring
- Investment in AI-driven diagnostic tools for early detection
- Expansion of personalized treatment plans based on genetic profiling

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Application: Clinical Diagnosis (Largest) vs. Research and Development (Fastest-Growing)

In the Japan Dry [Age Related Macular Degeneration](https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736) (AMD) Market, the application segment showcases a substantial distribution of shares across Clinical Diagnosis, Research and Development, and Patient Monitoring. Clinical Diagnosis remains the largest segment, driven by the increasing prevalence of AMD in an aging population. The demand for accurate diagnostic methods and technologies contributes significantly to its leading position. Meanwhile, Research and Development, although smaller in market share, is experiencing rapid growth as advancements in technology and increased investment in innovative treatments increase.

Clinical Diagnosis (Dominant) vs. Research and Development (Emerging)

Clinical Diagnosis is the dominant force within the Japan Dry AMD market, characterized by its extensive use in healthcare settings for the early detection and treatment of AMD. This segment benefits from established practices, significant healthcare provider reliance, and a strong focus on patient outcomes. Conversely, the Research and Development segment is emerging rapidly, fueled by heightened interest in novel therapies and solutions for AMD. Researchers are increasingly exploring gene therapies and new pharmaceutical options, making this segment vital for future growth and innovation in the market.

### By Treatment Type: Pharmacological Therapy (Largest) vs. Surgical Intervention (Fastest-Growing)

In the Japan Dry Age Related Macular Degeneration (AMD) market, the distribution of treatment types reveals that Pharmacological Therapy holds the largest market share. This category encompasses a variety of medication options designed to manage the progression of AMD. In contrast, while Surgical Intervention is smaller in market share, it is experiencing rapid growth due to advances in surgical techniques and technologies that improve patient outcomes. Nutritional Supplements also contribute to the treatment landscape but remain a less significant player compared to the other two segments.

The growth trends for these treatment types are primarily driven by increasing awareness of AMD and the aging population in Japan. As the prevalence of dry AMD rises, there is a continuous demand for more effective therapies, driving innovation in Pharmacological Therapy. Simultaneously, Surgical Intervention is rapidly gaining traction, spurred by technological advancements and positive patient feedback, suggesting a dynamic shift in how AMD is managed in clinical settings. Nutritional Supplements continue to play a supportive role, especially among those seeking preventative measures alongside primary treatments. Overall, the segment is positioned for substantial growth in the coming years as treatment options expand and evolve.

Pharmacological Therapy (Dominant) vs. Surgical Intervention (Emerging)

Pharmacological Therapy is the dominant treatment approach in the Japanese AMD market, primarily focusing on medications that slow disease progression. This segment benefits from a solid foundation of clinical research and patient acceptance. The major pharmaceutical companies are actively developing new drug formulations, enhancing efficacy and tolerability. On the other hand, Surgical Intervention represents an emerging segment, characterized by innovative and minimally invasive techniques that appeal to patients seeking quicker recovery times. This segment is rapidly evolving, influenced by technological advancements and improved surgical outcomes that foster greater acceptance among healthcare providers and patients alike. Both treatment types are essential in the holistic management of AMD, with their market positions reflecting ongoing trends in patient care and treatment science.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Japan Dry Age Related Macular Degeneration (AMD) market, patient demographics reveal significant insights, particularly in age groups and gender distribution. The largest segment, which comprises older adults aged 65 and above, accounts for a substantial population of AMD patients, highlighting the condition's prevalence among the elderly. Meanwhile, while gender distribution is relatively balanced, females demonstrate a slightly higher representation due to factors such as extended life expectancy and genetic predisposition. This creates a pronounced emphasis on targeting older demographics for treatment and management.

Growth trends indicate a rising awareness and diagnosis of AMD, particularly among the elderly, as the aging population in Japan expands. In addition, younger segments are increasingly becoming more vigilant about eye health, contributing to early detection and intervention measures. Gender-specific marketing strategies are also emerging, as awareness campaigns focus on the unique needs of female patients, thus driving growth in this demographic. Continued advancements in treatment options and technology are expected to further enhance engagement across all patient segments.

Age Group: 65+ (Dominant) vs. Gender: Female (Emerging)

The Age Group segment of patients aged 65 and above remains dominant in the Japan Dry Age Related Macular Degeneration market, as this cohort is most susceptible to the condition. As individuals age, the likelihood of developing AMD increases significantly, positioning this group as crucial for targeted interventions and advancements in treatment options. On the other hand, the Gender segment, specifically female patients, is emerging as a key demographic. With growing awareness around AMD and its impact on life quality, women are more likely to seek preventive care and treatment options. This evolving dynamic necessitates tailored marketing approaches that address gender-specific concerns while emphasizing the critical nature of AMD treatment for all age categories.

### By Disease Stage: Intermediate Stage (Largest) vs. Late Stage (Fastest-Growing)

In the Japan Dry Age Related Macular Degeneration (AMD) market, the distribution of disease stages reveals significant insights into patient demographics and treatment protocols. The Intermediate Stage is currently the largest segment, indicating a substantial patient population that requires effective management to prevent advancement to Late Stage AMD. This segment's size underscores the importance of early diagnosis and monitoring as critical strategies in treating AMD within Japan's healthcare system.

Meanwhile, the Late Stage is recognized as the fastest-growing segment, fueled by rising awareness of AMD's impact and advancements in treatment methodologies. As more individuals are screened and diagnosed, the treatment options for those in Late Stage are evolving. This growth is likely to prompt further investments in therapeutic innovations and patient education to facilitate timely interventions and improved outcomes.

Intermediate Stage (Dominant) vs. Late Stage (Emerging)

The Intermediate Stage of Dry AMD is characterized by noticeable changes in vision, usually without significant symptoms, which can lead to undiagnosed cases prolonging treatment. This segment holds a dominant market position because it directly ties to preventive care strategies aimed at delaying progression to Late Stage AMD. In contrast, the Late Stage represents an emerging segment, marked by significant vision loss and the need for urgent therapeutic interventions. The accumulation of anti-VEGF treatments and surgical options signifies its burgeoning importance in the market. As patients transition from Intermediate to Late Stage, the healthcare system emphasizes the need for effective monitoring and management protocols to mitigate the risk of severe visual impairment.

## Competitive Benchmarking

The Dry Age Related Macular Degeneration Amd Market in Japan is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Roche (Switzerland), Novartis (Switzerland), and Regeneron Pharmaceuticals (USA) are actively engaged in enhancing their product offerings and expanding their market presence. Roche (Switzerland) focuses on developing advanced therapeutic solutions, leveraging its strong R&D capabilities to introduce novel treatments. Novartis (Switzerland) emphasizes strategic collaborations to enhance its portfolio, while Regeneron Pharmaceuticals (USA) is known for its commitment to innovation, particularly in the field of biologics. Collectively, these strategies contribute to a dynamic competitive environment, where companies are not only vying for market share but also striving to lead in technological advancements.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players holding significant shares. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation and improves patient outcomes.

In December 2025, Bayer (Germany) announced a strategic partnership with a leading Japanese biotech firm to co-develop a new treatment for dry AMD. This collaboration is expected to leverage Bayer's extensive experience in ophthalmology and the local firm's insights into the Japanese market, potentially accelerating the development and commercialization of innovative therapies. Such partnerships are indicative of a broader trend where companies seek to combine strengths to enhance their competitive positioning.

In November 2025, Santen Pharmaceutical (Japan) launched a new digital health initiative aimed at improving patient engagement and adherence to treatment regimens for AMD. This initiative reflects a growing recognition of the importance of digital tools in managing chronic conditions, suggesting that Santen is positioning itself as a leader in integrating technology with healthcare solutions. The strategic importance of this move lies in its potential to enhance patient outcomes and foster loyalty in a competitive market.

In October 2025, Astellas Pharma (Japan) expanded its research capabilities by establishing a new R&D center focused on ophthalmic diseases, including dry AMD. This investment underscores Astellas' commitment to innovation and its strategic focus on addressing unmet medical needs in the ophthalmology space. The establishment of this center is likely to enhance Astellas' competitive edge by facilitating the development of cutting-edge therapies.

As of January 2026, the competitive trends in the Dry Age Related Macular Degeneration Amd Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

## Recent News & Developments

The Japan Dry Age-Related Macular Degeneration (AMD) Market has recently seen significant news developments and changes. In October 2023, Genentech announced progress in their clinical trial regarding innovative treatments for AMD, potentially impacting patient outcomes in Japan. 

Additionally, AbbVie and Horizon Therapeutics have broadened their collaborative efforts to accelerate research in AMD therapies, contributing to the evolving landscape of this market. Major players like Novartis and Roche have reported increased market valuation as a result of heightened demand for AMD treatments amid Japan's aging population. Notable growth in research and development expenditure in the ophthalmic segment, particularly focusing on dry AMD, has been observed, reflecting Japan's commitment to enhancing eye health care. Companies such as Astellas Pharma and Santen Pharmaceutical are aligning their strategies to capture market opportunities, following trends in regenerative treatments. 

Furthermore, in August 2022, Eyenovia announced a strategic partnership with a local firm to enhance the reach of its innovative delivery systems in Japan, thus diversifying treatment modalities in AMD. The collaborative efforts and rising investments have kept the Japanese AMD market dynamic, catering to the growing need for effective treatment solutions in a rapidly aging society.

## Report Scope

| MARKET SIZE 2024 | 297.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 322.19(USD Million) |
| MARKET SIZE 2035 | 660.62(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.52% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (JP), Novartis (JP), Regeneron Pharmaceuticals (JP), Bayer (JP), Pfizer (JP), Santen Pharmaceutical (JP), Astellas Pharma (JP), Otsuka Pharmaceutical (JP), Eisai (JP) |
| Segments Covered | Application, Treatment Type, Patient Demographics, Disease Stage |
| Key Market Opportunities | Emergence of innovative therapies and technologies addressing unmet needs in the Japan Dry Age Related Macular Degeneration Amd Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in Japan's Dry Age Related Macular Degeneration market. |
| Countries Covered | Japan |

## Frequently Asked Questions

**Q: What is the current market valuation of the Japan Dry Age Related Macular Degeneration AMD market?**
A: The market valuation was 297.5 USD Million in 2024.

**Q: What is the projected market size for the Japan Dry Age Related Macular Degeneration AMD market by 2035?**
A: The projected market size is expected to reach 660.62 USD Million by 2035.

**Q: What is the expected CAGR for the Japan Dry Age Related Macular Degeneration AMD market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 7.52%.

**Q: Which companies are the key players in the Japan Dry Age Related Macular Degeneration AMD market?**
A: Key players include Roche, Novartis, Regeneron Pharmaceuticals, Bayer, Pfizer, Santen Pharmaceutical, Astellas Pharma, Otsuka Pharmaceutical, and Eisai.

**Q: What are the main application segments in the Japan Dry Age Related Macular Degeneration AMD market?**
A: The main application segments include Clinical Diagnosis, Research and Development, and Patient Monitoring.

**Q: How did the Patient Monitoring segment perform in terms of valuation?**
A: The Patient Monitoring segment was valued at 134.0 USD Million in 2024 and is projected to reach 290.16 USD Million by 2035.

**Q: What treatment types are included in the Japan Dry Age Related Macular Degeneration AMD market?**
A: The treatment types include Pharmacological Therapy, Surgical Intervention, and Nutritional Supplements.

**Q: What was the valuation of the Pharmacological Therapy segment in 2024?**
A: The Pharmacological Therapy segment was valued at 120.0 USD Million in 2024.

**Q: How does the market segment by disease stage appear in terms of valuation?**
A: The Early Stage segment was valued at 89.25 USD Million, while the Late Stage segment was valued at 89.75 USD Million in 2024.

**Q: What demographic factors are considered in the Japan Dry Age Related Macular Degeneration AMD market?**
A: Demographic factors include Age Group, Gender, and Socioeconomic Status.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/japan-dry-age-related-macular-degeneration-market-44897*